MYOM2 and cancer: The ΔM51 mutation ablates wild type (WT) M protein's ability to inhibit cellular antiviral gene expression [6–8], while still allowing VSV to replicate in and kill cancer cells, as many cancers have defective type I interferon (IFN) antiviral responses.